Navigation Links
Taksta™ (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients
Date:11/3/2011

ANAHEIM, Calif., Nov. 3, 2011 /PRNewswire/ -- Cempra Pharmaceuticals will be presenting data demonstrating Taksta's activity against Methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from cystic fibrosis (CF) patients and demonstrating solithromycin's anti-inflammatory activity in a human lung epithelial in vitro model at the 25th Annual North American Cystic Fibrosis Conference in Anaheim, California.  Both studies will be presented during poster abstract sessions at 11:50 a.m. to 1:50 p.m. PDT, Nov. 3, and 4 to 6 p.m. PDT, Nov. 4, in Hall C in the Anaheim Convention Center.

Taksta (fusidic acid) is active against MRSA strains isolated from CF patients

Pulmonary MRSA infections in CF patients have been gaining increased attention because studies have shown that pulmonary function declines and mortality rates increase with MRSA infection.  The prevalence of hospital-acquired or community-acquired MRSA in the respiratory tract of individuals with CF has increased dramatically.  Fernandes et al. (Abst. # 285) investigated whether fusidic acid, shown to be active against MRSA isolated from other infections such as skin and skin structure infections, would be active against MRSA isolated from CF patients.  Forty strains isolated from the sputum of CF patients were tested against fusidic acid and comparator antibiotics, such as vancomycin, linezolid and daptomycin.  Fusidic acid demonstrated an MIC90 of 0.25 mg/L indicating that Taksta has potential for treating MRSA infection in CF patients.

Macrolides, including solithromycin (CEM-101), demonstrate anti-inflammatory activity in an airway anti-inflammation model

Macrolide antibiotics prolong survival in patients with diffuse panbronchiolitis, a condition that shares features with CF.  Macrolides are known to have anti-inflammatory activity and it has been hypothesized that these immunomodulatory properties could mediate their therapeutic effects.  Earlier work showed that pretreatment of primary human bronchial epithelial cultures with azithromycin prevented up-regulation of inflammatory and defense response genes generated by exposure to supernatant from mucopurulent material (SMM) from CF airways.  In this study, Ribeiro et al. (Abst. # 219) showed that pretreatment with solithromycin, along with azithromycin and telithromycin, inhibited SMM-induced expression of mRNA of inflammatory genes, particularly MUC5B (mucin-5B) and MUC5AC (mucin-5AC).  Because of chronic lung inflammation found in CF patients, the anti-inflammatory activity demonstrated in this study could provide a path for the development of new therapeutic agents for CF.

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical unmet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and skin and skin structure infections. Our two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its proprietary macrolide library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.

Contacts:

Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com

Prabhavathi Fernandes, Ph.D.
President and Chief Executive Officer
Cempra Pharmaceuticals
pfernandes@cempra.com


'/>"/>
SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
2. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
5. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
6. RVX-208 Data Demonstrates Increase in Functional HDL Particles
7. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
8. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
9. Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences
10. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
11. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):